Background
Methods
Study subjects and sampling
Titration of blood with LMWH
Viscoelastic coagulation analysis
Thromboelastometry
Free oscillation rheometry (FOR)
Statistical analysis
Results
Measures of clot initiation were prolonged by increasing doses of LMWH
Manufacturer’s reference range | 0 IU/mL | Enoxaparin | Enoxaparin | Enoxaparin | Tinzaparin | Tinzaparin | Tinzaparin | Enoxaparin vs Tinzaparin | Enoxaparin | Tinzaparin | |
---|---|---|---|---|---|---|---|---|---|---|---|
0.5 IU/mL | 1.0 IU/mL | 1.5 IU/mL | 0.5 IU/mL | 1.0 IU/mL | 1.5 IU/mL | ANOVA❖ | Spearman (Rho, P) | Spearman (Rho, P) | |||
ROTEM
| |||||||||||
CT (s) | 100-240 | 178 ± 38 | 191 ± 89 | 214 ± 109 | 249 ± 94 | 223 ± 53 | 289 ± 84 | 326 ± 125 | P < 0.01 | 0.62, P < 0.01 | 0.70, P < 0.01 |
CFT (s) | 30-110 | 77 ± 23 | 87 ± 21 | 85 ± 16 | 83 ± 22 | 74 ± 27 | 84 ± 45 | 80 ± 21 | P < 0.05 | N/S | N/S |
Angle (°) | 70-83 | 75 ± 4 | 74 ± 4 | 75 ± 3 | 73 ± 4 | 75 ± 5 | 73 ± 5 | 73 ± 4 | N/S | N/S | N/S |
MCF (mm) | 50-72 | 62 ± 5 | 61 ± 7 | 63 ± 5 | 63 ± 6 | 68 ± 7 | 64 ± 8 | 65 ± 6 | N/S | N/S | N/S |
ML (%) | <15 | 8 ± 4 | 6 ± 3 | 5 ± 4 | 2 ± 5 | 5 ± 4 | 6 ± 4 | 2 ± 4 | N/S | −0.36, P < 0.05 | N/S |
FOR (ReoRox)
| |||||||||||
COT1 (s) | 20-35 | 30 ± 5 | 35 ± 7 | 39 ± 8 | 38 ± 11 | 36 ± 4 | 45 ± 9 | 48 ± 15 | P < 0.01 | 0.58, P < 0.01 | 0.77, P < 0.01 |
COT2 (s) | 30-90 | 65 ± 11 | 76 ± 13 | 82 ± 14 | 85 ± 20 | 74 ± 5 | 91 ± 16 | 108 ± 29 | N/S | 0.54, P < 0.01 | 0.84, P < 0.01 |
COT2-COT1 (s) | 10-55 | 34 ± 13 | 41 ± 8 | 43 ± 9 | 46 ± 10 | 38 ± 4 | 46 ± 11 | 51 ± 15 | P < 0.05 | 0.47, P < 0.01 | 0.79, P < 0.01 |
Slope (Pa/min) | 45-145 | 99 ± 87 | 121 ± 82 | 126 ± 88 | 132 ± 76 | 118 ± 90 | 138 ± 94* | 109 ± 88 | P < 0.01 | N/S | N/S |
G’max (Pa) | 770-2180 | 1629 ± 617 | 1777 ± 662 | 1831 ± 701 | 1612 ± 612 | 1656 ± 692 | 2069 ± 665 | 1615 ± 641 | N/S | N/S | N/S |
Clot SR (%) | 10-25 | 17 ± 4 | 14 ± 5 | 16 ± 4 | 13 ± 6 | 15 ± 5 | 13 ± 6 | 11 ± 7 | N/S | N/S | −0.41, P < 0.05 |